Abstract
An asymptomatic, 29-year-old woman was referred to our hospital before surgery because in the basic study of hemostasis she showed a prolonged thrombin time (TT) and a normal reptilase time (RT). She had not received any anticoagulants so, to account for these abnormal results the presence of an inhibitor or a dysfibrinogenemia was suspected. A 1:1 mixture of the patient’s plasma with control plasma did not correct the TT. Dysfibrinogenemia was excluded because the defibrinated plasma retained the inhibitory activity when mixed with normal plasma. When 0.02 mg/ml of Protamine Sulphate (a concentration that neutralizes 1 U/mL of heparin in normal plasma) was added to the patient’s plasma, the inhibitory activity did not disappear. IgG from the patient and from normal serum was isolated. The patient’s IgG was able to prolong the TT of a normal plasma and of a purified fibrinogen. The patient IgG did not impair the catalytic activity of thrombin, because no difference was observed in the hydrolysis of S-2238 by 1 U NIH human thrombin with normal or patient IgG. The time course of the thrombin–mediated fibrinopeptide-release from normal fibrinogen with the patient’s IgG, showed a delay in the fibrinopeptide B (FPB) release without affecting the fibrinopeptide A (FPA) release. This patient has an IgG antibody that delays fibrinopeptide B release of fibrinogenReferences
- Chapman GS, George CB, Danley DL. Heparin-like anticoagulant associated with plasma cell myeloma. Am J Clin Pathol. 1985; 83:764-6. PubMed|Google Scholar
- Tefferi A, Owen BA, Nichols WL, Witzig TE, Owen WG. Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma. Blood. 1989; 74:252-4. PubMed|Google Scholar
- Khoory MS, Nesheim ME, Bowie EJ, Mann KG. Circulating heparin sulphate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Invest. 1980; 65:666-74. PubMed|Google Scholar
- Bussel JB, Steinherz PG, Miller DR, Hilgartner MW. A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukaemia. Am J Hematol. 1984; 16:83-90. PubMed|Google Scholar
- Kehl M, Lottspeich F, Henschen A. Analysis of human fibrinopeptides by high-performance liquid chromatography. Hoppe-Seyler’s Z Physiol Chem. 1981; 362:1661-4. PubMed|Google Scholar
- Nawarawong W, Wyshock E, Meloni FJ, Weitz J, Schmaier AH. The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. Br J Haematol. 1991; 79:296-301. PubMed|https://doi.org/10.1111/j.1365-2141.1991.tb04536.x|Google Scholar
- Davey FR, Gordon GB, Boral LI, Gottlieb AJ. Gamma globulin inhibition of fibrin clot formation. Ann Clin Lab Sci. 1976; 6:72-7. PubMed|Google Scholar
- ohler A, Redondo M, Lammle B. Increased thrombin time in a patient wih multiple myeloma. Ther Umsch. 1999; 56:491-4. PubMed|https://doi.org/10.1024/0040-5930.56.9.491|Google Scholar
- Gris JC, Schved JF, Branger B, Aguilar-Martinez P, Vécina F, Oulès R. Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorragic syndrome. Blood Coagul Fibrinolysis. 1992; 3:519-29. PubMed|https://doi.org/10.1097/00001721-199210000-00002|Google Scholar
- Hoots WK, Carrell NA, Wagner RH, Cooper HA, McDonagh J. A naturally occurring antibody that inhibits fibrin monomer polymerization. N Engl J Med. 1981; 304:857-61. PubMed|Google Scholar
- Ghosh S, McEvoy P, McVerry BA. Idiopathic autoantibody that inhibits fibrin monomer polymerization. Br J Haematol. 1983; 53:65-72. PubMed|Google Scholar
- Ruiz-Arguelles A. Spontaneous reversal of acquired auto immune dysfibrinogenemia probably due to an antiidiotypic autoantibody directed to an interspecies cross-reactive idio-type expressed on fibrinogen antibodies. J Clin Invest. 1988; 82:958-63. PubMed|Google Scholar
- Marciniak E, Greenwood MF. Acquired coagulation inhibitor delaying fibrinopeptide release. Blood. 1979; 53:81-92. PubMed|Google Scholar
- Hanss M, Biot F. A Database For Human Fibrinogen Variants. Ann N. 2001; 936:89-90. Google Scholar